Combined treatment with keratinocyte growth factor and epidermal growth factor inhibitor
OwnerPenelope Elizabeth Miller, James Dale Moyerinventors
Life of this patent
Estimating the term…
Abstract
The present invention relates to compositions and methods for treating the epithelial toxicity caused by administering to a human cancer patient an epidermal growth factor receptor (EGFR) inhibitor. The pharmaceutical composition preferably comprises an EGFR inhibitor and a keratinocyte growth factor (KGF) in a pharmaceutically-acceptable carrier. The method of treatment comprises co-administering to the patient a therapeutically effective amount of KGF with the EGFR inhibitor.
Claims16
A method of treating the epithelial toxicity resulting from administration to a patient of the EGFR inhibitor N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazoline amine or a pharmaceutically acceptable salt thereof, comprising co-administering to the patient a therapeutically effective amount of KGF with the EGFR inhibitor.
A method of preparing a pharmaceutical composition useful for treating the epithelial toxicity resulting from administration to a patient of an EGFR inhibitor, comprising combining a KGF with the EGFR inhibitor.
Dependencies are inferred from the claim text.